Brief: Theraclion: Last Patient Of First SONOVEIN U.S. Study Has Been Treated
Oct 17 (Reuters) - Theraclion SA ALTHER.PA :
* THERACLION: LAST PATIENT OF FIRST SONOVEIN® US STUDY HAS
BEEN
TREATED
* FOLLOWING UPCOMING CLOSURE OF THIS CLINICAL TRIAL, A FULL
PIVOTAL STUDY FOR FDA REVIEW SHOULD TAKE PLACE NEXT
Source text for Eikon: ID:nBw32tskHa
Further company coverage: ALTHER.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Theraclion SA
See all newsBrief: Theraclion Appoints Claude Lenoir As Interim Chairman
Brief: Theraclion Secures U.S. Reimbursement Milestone for Sonovein With New Category III CPT Code
French and Benelux stocks-Factors to watch
Brief: Inner Mongolia Furui Medical Raises Stake In Theraclion
Brief: French medical technology company Theraclion strikes partnership with Chinese company Furui and names new CEO